Van Buren et al., 2009 - Google Patents
Elucidation of two major aggregation pathways in an IgG2 antibodyVan Buren et al., 2009
View HTML- Document ID
- 9233669765362300523
- Author
- Van Buren N
- Rehder D
- Gadgil H
- Matsumura M
- Jacob J
- Publication year
- Publication venue
- Journal of pharmaceutical sciences
External Links
Snippet
Two major aggregation pathways observed in an IgG2 molecule are described. Different aggregate species generated by long-term incubation of the antibody at 37° C were collected by a semi-preparative size exclusion chromatography method. These purified …
- 238000004220 aggregation 0 title abstract description 76
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
- A61K47/16—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Buren et al. | Elucidation of two major aggregation pathways in an IgG2 antibody | |
Neergaard et al. | Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass | |
JP5553963B2 (en) | Methods for refolding recombinant antibodies | |
Iacob et al. | Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements | |
Paul et al. | Structure and function of purified monoclonal antibody dimers induced by different stress conditions | |
Cordoba et al. | Non-enzymatic hinge region fragmentation of antibodies in solution | |
Lee et al. | Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product | |
Singh et al. | Effect of polysorbate 80 quality on photostability of a monoclonal antibody | |
Yu et al. | Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development | |
Yan et al. | Versatile, sensitive, and robust native LC–MS platform for intact mass analysis of protein drugs | |
Liu et al. | Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry | |
Franey et al. | Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates | |
Svilenov et al. | The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage | |
Zheng et al. | Investigating the degradation behaviors of a therapeutic monoclonal antibody associated with pH and buffer species | |
US20160231329A1 (en) | A method for analysing a sample immunoglobulin molecules | |
Perico et al. | Conformational implications of an inversed pH-dependent antibody aggregation | |
Arora et al. | Correlating the effects of antimicrobial preservatives on conformational stability, aggregation propensity, and backbone flexibility of an IgG1 mAb | |
Chakraborty et al. | Isolation of fibronectin type III like peptide from human placental extract used as wound healer | |
EP3160511B1 (en) | Protein formulations | |
Li et al. | Identification and characterization of monoclonal antibody fragments cleaved at the complementarity determining region using orthogonal analytical methods | |
Chen et al. | The use of native cation‐exchange chromatography to study aggregation and phase separation of monoclonal antibodies | |
Jiang et al. | Evaluation of heavy-chain C-terminal deletion on product quality and pharmacokinetics of monoclonal antibodies | |
Liu et al. | Characterization of recombinant monoclonal antibody charge variants using WCX chromatography, icIEF and LC-MS/MS | |
Majumder et al. | Impact of buffers on colloidal property and aggregation propensities of a bispecific antibody | |
Whitaker et al. | Developability assessment of physicochemical properties and stability profiles of HIV-1 BG505 SOSIP. 664 and BG505 SOSIP. v4. 1-GT1. 1 gp140 envelope glycoprotein trimers as candidate vaccine antigens |